about
Molecular physiology of mammalian glucokinaseThe hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic ratsInsulin-receptor substrate-2 (irs-2) is required for maintaining glucokinase and glucokinase regulatory protein expression in mouse liverAntidiabetic effects of glucokinase regulatory protein small-molecule disruptorsAtherogenic, fibrotic and glucose utilising actions of glucokinase activators on vascular endothelium and smooth muscleGlucokinase activators (GKAs) promise a new pharmacotherapy for diabetics.Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humansEstimating hepatic glucokinase activity using a simple model of lactate kinetics.Glucokinase activators for diabetes therapy: May 2010 status reportBrought to life: targeted activation of enzyme function with small molecules.Hyperglycemia Induced by Glucokinase Deficiency Accelerates Atherosclerosis Development and Impairs Lesion Regression in Combined Heterozygous Glucokinase and the Apolipoprotein E-Knockout Mice.Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.Identification of mangiferin as a potential Glucokinase activator by structure-based virtual ligand screening.Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes.Glucokinase activators.A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014.Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.Targeting hepatic glucokinase in type 2 diabetes: weighing the benefits and risks.Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp.Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities.The relationship of glucokinase activator-induced hypoglycemia with arteriopathy, neuronal necrosis, and peripheral neuropathy in nonclinical studies.Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
P2860
Q24653018-6405FF99-102C-4A79-B5F9-B27C65AA7A10Q27333171-52978C93-51FB-4E78-8661-563B84F0074CQ27334742-84523647-E43C-46A9-A893-DEA480EE9331Q27687521-7B07EE4F-D99D-4BEA-8F0F-B4932DA0A56CQ33593675-4E25F468-20D2-4E8C-9C63-382A410CA7A3Q33719119-FC142C86-4B8D-46F4-95E8-99A3C59A9B97Q34998302-8CD92450-CC9D-45F9-9A5B-7A9FF0101C4FQ35898249-560A1F2D-8872-4795-A982-8896DD5FD9B1Q36783849-B0E14BD6-559C-49EE-B19B-279923C8996EQ37192865-6EF257D8-34B6-4511-975C-6450074E38CBQ37330179-D8DBD467-DE11-4969-973B-13F8C3FB3A45Q37665590-CFC775AE-218E-4C4F-A314-320EC2D6A3D0Q37710606-8B4B7062-E6B2-4E21-B239-697C35D667A6Q38071706-CE528877-BF25-4731-8A84-0E9DAA06C92EQ38162928-D669A390-A790-4E41-867E-C005B13C3611Q38211348-1BA4FDC2-65BE-46D9-9CF1-24AD5D96A8DDQ38529399-2759F5F9-FDBF-42F7-BADA-62DC8D510F17Q41866371-14AAE288-A61D-458F-AD49-B7302930398AQ43764267-E4D330EF-CCE9-4BD8-93F8-24AE38CA39E1Q43826389-AE383D78-A7C6-4B29-A33D-A829031B0232Q44424660-AB0D75E5-8455-43F1-82C1-D75E8D2A0064Q46713473-4E409E41-9F0D-43C4-AC8C-069B2ED1EC5BQ46900970-2FCB1477-C0BF-428D-A151-CF4210A6F054Q51354362-1D3B5B58-CA40-4D98-AF0E-BA7AC6A53293
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Glucokinase activators in diabetes management.
@en
Glucokinase activators in diabetes management.
@nl
type
label
Glucokinase activators in diabetes management.
@en
Glucokinase activators in diabetes management.
@nl
prefLabel
Glucokinase activators in diabetes management.
@en
Glucokinase activators in diabetes management.
@nl
P2860
P1476
Glucokinase activators in diabetes management.
@en
P2093
Brendan Leighton
Matthew Coghlan
P2860
P304
P356
10.1517/13543784.17.2.145
P407
P577
2008-02-01T00:00:00Z